Code intelligence

J9312 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance matched to code J9312.

Elevated code riskView HCPCS detail

Signal breakdown

5 shown · 5 total in platform

Risk: Elevated

Critical

High

40%

Routine

60%

Low

New this month

—

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: TRUXIMA (RITUXIMAB-ABBS) — Type 5 - New Formulation or New Manufacturer

Policy FDA-BLA761088 · Oncology

High

New FDA drug approval. Coverage and billing pathway depend on the FDA label and applicable Medicare LCDs/NCDs — for very recent approvals the label may not be posted yet. Verify against the FDA label and current coverage policy before billing.

View alert

LCD L38268: Immune Thrombocytopenia (ITP) Therapy — CGS

Policy LCD-L38268 · Hematology

Routine

New LCD for ITP effective March 2026 impacts billing practices.

View alert

Proposed LCD DL39297: Off-label Use of Rituximab and Rituximab Biosimilars — NGS

Policy LCD-DL39297 · Oncology

High

Impact of proposed LCD on Rituximab billing practices.

View alert

LCD L39297: Off-label Use of Rituximab and Rituximab Biosimilars — NGS

Policy LCD-L39297 · Oncology

Routine

Off-label Rituximab use may impact Medicare billing.

View alert

LCD L38920: Off-label Use of Rituximab and Rituximab Biosimilars — CGS

Policy LCD-L38920 · Oncology

Routine

Prepare for billing changes on Rituximab off-label use.

View alert

Audit documentation

Building an audit file that includes J9312?

The Tripwire Audit Pack exports 12 months of Oncology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Oncology audit pack — $349One-time purchase · not a subscription